How to deal with thrombocytopenia after eltrombopag chemotherapy?

Thrombocytopenia after eltrombopag chemotherapy is one of the common side effects during chemotherapy. Thrombocytopenia may lead to an increased risk of bleeding and therefore requires prompt management.

Perform routine blood tests regularly and pay close attention to changes in platelet count. When the platelet count falls below a safe level (usually considered to be less than 50×10^9/L), appropriate measures should be taken. Depending on the degree of thrombocytopenia, doctors may consider using drugs that promote platelet production, such as interleukin-11, TPIAO, etc. These drugs stimulate the bone marrow to produce more platelets, thereby helping to increase platelet counts.

Eltrombopag itself is also a thrombopoietin receptor agonist, which acts by inducing stimulation of megakaryocyte differentiation and proliferation. If appropriate, your doctor may adjust the dose of eltrombopag or continue its use to improve thrombocytopenia.

For patients with very low platelet counts or severe bleeding symptoms, platelet transfusions may be needed. This is a quick and effective way to increase platelet counts and immediately reduce the risk of bleeding.

When platelet counts are low, patients should reduce activity and avoid strenuous exercise to prevent injury and bleeding. Avoid using drugs that affect platelet function, such as nonsteroidal anti-inflammatory drugs. Keep the stool smooth and avoid risks such as intracranial hemorrhage caused by straining to defecate.

In summary, the treatment of thrombocytopenia after eltrombopag chemotherapy requires comprehensive consideration of the patient's specific illness and physical condition. Through the comprehensive application of drug therapy, blood transfusion therapy, and general management measures, platelet counts can be effectively increased and the risk of bleeding reduced. At the same time, psychological support and health education are also indispensable.